938 results on '"Rubin, Lewis"'
Search Results
2. Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?
3. Recommendations for the Use of the Veggie Meter® for Spectroscopy-Based Skin Carotenoid Measurements in the Research Setting
4. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
5. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
6. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study
7. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects
8. Metabolic Effects of Inflammation on Vitamin A and Carotenoids in Humans and Animal Models
9. β-Carotene exerts anti-colon cancer effects by regulating M2 macrophages and activated fibroblasts
10. Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study
11. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
12. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial
13. β-Carotene 15,15′-oxygenase inhibits cancer cell stemness and metastasis by regulating differentiation-related miRNAs in human neuroblastoma
14. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
15. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score
16. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
17. Enhanced Expression of Transient Receptor Potential Channels in Idiopathic Pulmonary Arterial Hypertension
18. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study
19. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial
20. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
21. NO Hyperpolarizes Pulmonary Artery Smooth Muscle Cells and Decreases the Intracellular Ca$^{2+}$ Concentration by Activating Voltage-Gated K$^{+}$ Channels
22. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
23. Blood Cytokine Profiles Associated with Distinct Patterns of Bronchopulmonary Dysplasia among Extremely Low Birth Weight Infants
24. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial
25. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases: Insights From Pulmonary Arterial Hypertension
26. Role of macular xanthophylls in prevention of common neovascular retinopathies: Retinopathy of prematurity and diabetic retinopathy
27. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study
28. Effect of Macitentan on Hospitalizations: Results From the SERAPHIN Trial
29. Chronic thromboembolic pulmonary hypertension
30. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
31. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients
32. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
33. Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era: Importance of Serial Hemodynamic Measurements
34. Cor Pulmonale Revisited. From Ferrer and Harvey to the Present
35. β-Carotene regulates expression of β-carotene 15,15′-monoxygenase in human alveolar epithelial cells
36. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study): A Randomized Controlled Trial
37. Contemporary Trends in the Diagnosis and Management of Pulmonary Arterial Hypertension: An Initiative to Close the Care Gap
38. Pulmonary hypoplasia resulting from prolonged rupture of membranes: A distinct clinical entity with instructive experimental models
39. MEF2 Transcription Factors Regulate Human Trophoblast Invasion and Differentiation [33P]
40. Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension
41. Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
42. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension
43. Polymorphisms within ASTN2 gene are associated with age at onset of Alzheimer’s disease
44. Developing a Heart Score: Next Steps
45. Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension: The SUPER-2 Study
46. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
47. Worldwide Physician Education and Training in Pulmonary Hypertension: Pulmonary Vascular Disease: The Global Perspective
48. Hepatic stellate cells are an important cellular site for β-carotene conversion to retinoid
49. Selexipag for the Treatment of Pulmonary Arterial Hypertension
50. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.